Multi-Cancer Early Detection Tests

Share

Get one blood test. Detect up to 10, 20 or even more types of cancer.

That is the potential for a new category of cancer early detection tests currently being developed and tested by scientists. A breakthrough like this could revolutionize the ability to detect cancer at its earliest, most treatable stages, including for dozens of cancers for which there is no current screening test.

They call it a Multi-Cancer Early Detection (MCED) test. We call it an innovative and potentially game-changing advancement for cancer patients.

Now we need to ensure that, if approved by the FDA and shown to have clinical benefit, millions of people, especially older Americans at higher risk for cancer, will have the test covered by their health insurance plan. We are asking Congress to pass legislation that lays the groundwork for this to happen.

Latest Updates

September 22, 2021
National

Washington, DC – The American Cancer Society Cancer Action Network (ACS CAN) launched a new advertising campaign this week highlighting its strong support for the Medicare Multi-Cancer Early Detection Screening Coverage Act (H.R. 1946/S. 1873), legislation that aims to improve access to new and innovative cancer screenings among Medicare beneficiaries

Multi-Cancer Early Detection Tests Resources

On March 16, 2021, Representatives Terri Sewell (D-AL) and Jodey Arrington (R-TX) re-introduced the Multi- Cancer Early Detection Screening Coverage Act, H.R. 1946. On May 27, 2021, Senators Mike Crapo (R-ID) and Michael Bennet (D-CO) introduced the Senate companion, S. 1873. This legislation will create a pathway to allow Medicare to cover multi-cancer screening tests once the tests have been approved by the FDA. ACS CAN has endorsed this legislation.

Early screening for cancer is important because when detected at later stages, treatments are more limited, and outcomes are generally poorer. Newer, innovative multi-cancer screening technology has the potential to detect more cancers at earlier stages. Several private and academic entities are currently developing multi-cancer early detection blood-based tests. Published data indicate that some of these tests can screen for many cancers at the same time, including some rare cancers.